POLYCYTHEMIA VERA

This study tests whether adding iadademstat to the standard drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 62 adults whose disease has progressed to a more aggressive phase will be ra…

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…

This study follows 36 Italian adults with polycythemia vera, a blood cancer, who have been responding well to the drug Ropeginterferon alfa-2b for at least two years. Researchers will check every six months whether their red blood cell levels stay controlled and the disease does …

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This study tests a new drug called sapablursen in 250 people with polycythemia vera, a condition where the body makes too many red blood cells. The drug is added to standard treatment to see if it can reduce the need for regular blood removal (phlebotomy). Participants will recei…

This study tests whether the drug ruxolitinib works better than standard treatments (interferon or hydroxycarbamide) for people with high-risk polycythemia vera, a blood cancer that causes too many red blood cells. About 586 adults aged 18 and older with high-risk features will b…

This study follows 200 adults with polycythemia vera (a rare blood cancer) who do not have an enlarged spleen. Researchers will track how well the drug ropeginterferon alfa-2b controls symptoms and blood counts in everyday medical practice. The goal is to understand real-world be…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already doing well on the drug bomedemstat. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants will conti…

This study tests a new drug, givinostat, against the current standard treatment hydroxyurea in 220 adults with a high-risk form of polycythemia vera, a blood cancer that increases red blood cells. The goal is to see if givinostat better controls blood counts and spleen size witho…

This study compares two newer blood thinners (apixaban and rivaroxaban) against daily low-dose aspirin to prevent dangerous blood clots in people with JAK2-positive myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. About 1,300 high-risk adults (over 60 or wit…

This study tests whether the drug ruxolitinib can reduce symptoms like fatigue, itching, and night sweats in people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV) who have significant symptom burden. About 60 adults will take ruxolitinib and be monitored f…

This study tests N-acetylcysteine (N-AC), a supplement, in 27 adults with certain blood cancers (myeloproliferative neoplasms). The goal is to find the best dose that reduces symptoms like fatigue and pain while being safe. Participants continue their usual treatments during the …

This study is testing whether a curcumin supplement (the active ingredient in turmeric) can lower inflammation and improve symptoms in people with certain blood disorders, including low-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). About 30 adults wi…

This study is looking at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease or predict its course. About 70 participants will …

This study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…

This study looks at people with a blood condition called essential thrombocythemia (ET) who later develop polycythemia vera (PV), a related disorder. Researchers want to find out what factors cause this change and whether these patients have different outcomes than those diagnose…